Glyxambi is FDA-approved to improve glycemic control in adults with type 2 diabetes when treatment with both empagliflozin and linagliptin is appropriate. Glyxambi can be part of a comprehensive treatment plan that also includes diet and exercise.
Glyxambi can also help lower the risk of cardiovascular death from heart attack, stroke, or heart failure in adults with type 2 diabetes and established cardiovascular disease.
Glyxambi is not effective in treating type 1 diabetes mellitus or diabetic ketoacidosis.